Approach to symptomatic coronary disease in the elderly: TIME to change?

Lancet

Volumn 358, Issue 9286, 2001, Pages 945-946

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FOLLOW UP; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE REVASCULARIZATION; HEART RUPTURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HORMONAL THERAPY; HUMAN; HYPOTENSION; MORTALITY; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0035934564     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06111-6     Document Type: Note

References (21)

1. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: A community-wide perspective
2. The exclusion of the elderly and women from clinical trials in acute myocardial infarction
3. Representation of elderly persons and women in published randomized trials of acute coronary syndromes
4. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S)
5. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) Trial
6. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID Trial
7. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >125 mg/dL treated with statins versus no lipid-lowering drug
8. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
9. Early revascularization in acute myocardial infarction complicated by cardiogenic shock
10. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
11. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
12. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
13. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study
14. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
15. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons
16. Heart failure with normal ejection fracton. The V-HeFT Study
17. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance
18. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction
19. The effect of digoxin on mortality and morbidity in patients with heart failure
20. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction (≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors
21. Systolic versus diastolic heart failure in community practice: Clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors